60 Degrees Pharmaceuticals Reports Clinical Improvement in All Five Completed Babesiosis Study Patients

• 60 Degrees Pharmaceuticals announced results showing clinical improvement in all five patients completing tafenoquine combination treatment for relapsing babesiosis.
• All five tested negative on conventional parasite tests; more sensitive testing detected residual infection in one patient.
• The company plans to pursue accelerated approval if its efficacy submission relies primarily on immunosuppressed patients with relapsing babesiosis.
• A separate randomized hospital trial is scheduled for unblinding in January 2027, with FDA regulatory discussions planned afterward.
• Tafenoquine is approved for malaria prevention in the United States, but not for babesiosis treatment or prevention.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-112698), on October 27, 2026, and is solely responsible for the information contained therein.